Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by GCS.
Page 2: 1 2 3 4 5 6 7 8 9
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
301 | 0 | 32 | 402 1966 MONATSHEFTE FUR CHEMIE UND VERWANDTE TEILE ANDERER WISSENSCHAFTEN 97(6):1648-& KOCH H; KOTLAN J THALIDOMIDE ANALOGUES | 15 | 25 |
302 | 4 | 19 | 612 1975 HAUTARZT 26(1):1-5 SHESKIN J THERAPEUTIC EFFECTS OF THALIDOMIDE IN LEPROSY REACTION | 22 | 25 |
303 | 2 | 8 | 713 1979 TERATOLOGY 19(3):341-344 JACKSON AJ; SCHUMACHER HJ TERATOGENIC ACTIVITY OF A THALIDOMIDE ANALOGOUS EM12 IN RATS ON A LOW-ZINC DIET | 2 | 25 |
304 | 4 | 7 | 772 1982 ACTA DERMATO-VENEREOLOGICA 62(5):449-450 BAHMER FA; ZAUN H; LUSZPINSKI P THALIDOMIDE TREATMENT OF RECURRENT ERYTHEMA MULTIFORME | 19 | 25 |
305 | 2 | 2 | 808 1983 BRITISH MEDICAL JOURNAL 287(6395):799-800 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 19 | 25 |
306 | 3 | 6 | 972 1988 LANCET 1(8589):827-827 VOGELSANG GB; SANTOS GW; COLVIN OM; CHEN TL THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 12 | 25 |
307 | 8 | 18 | 1062 1992 JOURNAL OF MEDICAL GENETICS 29(10):716-723 SMITHELLS RW; NEWMAN CGH RECOGNITION OF THALIDOMIDE DEFECTS | 9 | 25 |
308 | 5 | 21 | 1244 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 224(2):426-430 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production | 15 | 25 |
309 | 14 | 21 | 1312 1997 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 41(12):2797-2799 Piscitelli SC; Figg WD; Hahn B; Kelly G; Thomas S; Walker RE Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients | 22 | 25 |
310 | 4 | 5 | 1400 1998 ARCHIVES OF DERMATOLOGY 134(8):1045-1046 Rousseau L; Beylot-Barry M; Doutre MS; Beylot C Cutaneous sarcoidosis successfully treated with low doses of thalidomide | 12 | 25 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
311 | 22 | 42 | 1522 1999 BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 10 | 25 |
312 | 23 | 32 | 1545 1999 GASTROENTEROLOGY 117(6):1485-1488 Sands BE; Podolsky DK New life in a sleeper: Thalidomide and Crohn's disease | 8 | 25 |
313 | 3 | 14 | 1610 2000 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 23(3):319-321 Patt YZ; Hassan MM; Lozano RD; Ellis LM; Peterson JA; Waugh KA Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide | 14 | 25 |
314 | 13 | 36 | 2194 2002 GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
315 | 7 | 22 | 2253 2002 LEUKEMIA 16(1):1-6 Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Thalidomide for the treatment of patients with myelodysplastic syndromes | 14 | 25 |
316 | 5 | 20 | 238 1963 LANCET 1(729):1095-& SMITHELLS RW; LECK I INCIDENCE OF LIMB AND EAR DEFECTS SINCE WITHDRAWAL OF THALIDOMIDE | 2 | 24 |
317 | 14 | 20 | 385 1966 JOURNAL OF PATHOLOGY AND BACTERIOLOGY 91(2):511-& FABRO S; SMITH RL TERATOGENIC ACTIVITY OF THALIDOMIDE IN RABBIT | 15 | 24 |
318 | 0 | 2 | 776 1982 ARCHIVES OF DERMATOLOGY 118(11):875-875 TORRAS H; LECHA M; MASCARO JM THALIDOMIDE TREATMENT OF RECURRENT NECROTIC GIANT MUCOCUTANEOUS APHTHAE AND APHTHOSIS | 18 | 24 |
319 | 9 | 24 | 845 1984 BIOCHEMICAL PHARMACOLOGY 33(9):1471-1477 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - ACTIVATION OF THALIDOMIDE AND THALIDOMIDE ANALOGS TO PRODUCTS THAT INHIBIT THE ATTACHMENT OF CELLS TO CONCANAVALIN A COATED PLASTIC SURFACES | 15 | 24 |
320 | 5 | 19 | 1201 1995 JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 674(2):287-292 Weinz C; Blaschke G Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis | 11 | 24 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
321 | 2 | 3 | 1237 1996 ARCHIVES OF DERMATOLOGY 132(11):1392-1393 Dereure O; BassetSeguin N; Guilhou JJ Erosive lichen planus: Dramatic response to thalidomide | 14 | 24 |
322 | 9 | 11 | 1250 1996 BRITISH MEDICAL JOURNAL 313(7054):377-378 Powell RJ New roles for thalidomide | 18 | 24 |
323 | 4 | 22 | 1268 1996 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 18(1):59-72 Shannon EJ; Sandoval F Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells | 21 | 24 |
324 | 37 | 60 | 1433 1998 EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
325 | 21 | 27 | 1451 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 23 | 24 |
326 | 5 | 5 | 1461 1998 LANCET 352(9127):544-545 Stambe C; Wicks IP TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide | 10 | 24 |
327 | 0 | 0 | 1641 2000 BLOOD 96(11):168A-168A Rajkumar SV; Hayman S; Fonseca R; Dispenzieri A; Lacy MQ; Geyer S; Wellik L; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide plus dexamethasone (Thal/Dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM). | 0 | 24 |
328 | 19 | 36 | 2053 2002 BLOOD 99(3):834-839 Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM Efficacy and safety of thalidomide in patients with acute myeloid leukemia | 10 | 24 |
329 | 15 | 29 | 2156 2002 CHEST 122(1):227-232 Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE Thalidomide for chronic sarcoidosis | 4 | 24 |
330 | 37 | 67 | 2230 2002 JOURNAL OF IMMUNOLOGY 168(6):2644-2651 Majumdar S; Lamothe B; Aggarwal BB Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester | 12 | 24 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
331 | 3 | 8 | 242 1963 LANCET 2(730):405-& LINDAHLKIESSLIN.K; BOOK JA EFFECTS OF THALIDOMIDE ON HUMAN LEUCOCYTE CULTURES | 16 | 23 |
332 | 8 | 13 | 334 1965 EXPERIENTIA 21(11):672-& SAWIN PB; CRARY D; FOX RR; WUEST HM THALIDOMIDE MALFORMATIONS AND GENETIC BACKGROUND IN RABBIT | 9 | 23 |
333 | 6 | 13 | 403 1966 NATURE 210(5039):958-& HENDRICK.AG; AXELROD LR; CLAYBORN LD THALIDOMIDE SYNDROME IN BABOONS | 0 | 23 |
334 | 3 | 36 | 668 1978 INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY 57(4):317-332 GOIHMANYAHR M; CONVIT J; RODRIGUEZOCHOA G; ARANZAZU N; VILLALBAPIMENTEL L; OCANTO A; ELENADEGOMEZ M SIGNIFICANCE OF NEUTROPHIL ACTIVATION IN REACTIONAL LEPROMATOUS LEPROSY - EFFECTS OF THALIDOMIDE INVIVO AND INVITRO - ACTIVATION IN ADJUVANT DISEASE | 14 | 23 |
335 | 6 | 20 | 771 1982 ACTA DERMATO-VENEREOLOGICA 62(4):321-324 HASPER MF; KLOKKE AH THALIDOMIDE IN THE TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 17 | 23 |
336 | 0 | 4 | 939 1987 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 114(11):1387-1389 GNASSIA AM; GNASSIA RT; BONVALET D; PUISSANT A; GOUDAL H HISTIOCYTOSIS-X WITH VULVAR LOCALIZATION - DRAMATIC EFFECT OF THALIDOMIDE | 15 | 23 |
337 | 2 | 12 | 947 1987 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 413:181-187 CZEJKA MJ; KOCH HP DETERMINATION OF THALIDOMIDE AND ITS MAJOR METABOLITES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 22 | 23 |
338 | 19 | 39 | 998 1989 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 20(6):1060-1063 GRINSPAN D; BLANCO GF; AGUERO S TREATMENT OF APHTHAE WITH THALIDOMIDE | 9 | 23 |
339 | 2 | 34 | 1036 1991 BRITISH JOURNAL OF DERMATOLOGY 125(1):62-67 BURROWS NP; WALPORT MJ; HAMMOND AH; DAVEY N; JONES RR LUPUS-ERYTHEMATOSUS PROFUNDUS WITH PARTIAL C4-DEFICIENCY RESPONDING TO THALIDOMIDE | 12 | 23 |
340 | 11 | 31 | 1191 1995 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 49(1-2):1-6 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND GENETIC-DIFFERENCES IN DRUG-METABOLISM | 20 | 23 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
341 | 4 | 25 | 1236 1996 ANTICANCER RESEARCH 16(6B):3673-3677 Gutman M; Szold A; Ravid A; Lazauskas T; Merimsky O; Klausner JM Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo | 16 | 23 |
342 | 8 | 29 | 1378 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
343 | 11 | 60 | 1614 2000 AMERICAN JOURNAL OF NEURORADIOLOGY 21(5):881-890 Cha S; Knopp EA; Johnson G; Litt A; Glass J; Gruber ML; Lu S; Zagzag D Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin | 2 | 23 |
344 | 4 | 8 | 1677 2000 BLOOD 96(12):3995-3996 Koc S; Leisenring W; Flowers MED; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ Thalidomide for treatment of patients with chronic graft-versus-host disease | 14 | 23 |
345 | 1 | 3 | 1678 2000 BLOOD 96(12):4007-4007 Tefferi A; Elliott MA Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia | 15 | 23 |
346 | 61 | 96 | 1785 2000 SEMINARS IN HEMATOLOGY 37(1):5-14 Stirling DI Pharmacology of thalidomide | 21 | 23 |
347 | 12 | 22 | 1888 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):78-83 Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia | 12 | 23 |
348 | 10 | 17 | 446 1968 AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY 100(7):952-& GUSDON JP; COHEN C EFFECT OF THALIDOMIDE ON ANTIBODY RESPONSE | 21 | 22 |
349 | 3 | 4 | 1128 1994 BRITISH MEDICAL JOURNAL 308(6944):1635-1636 MCBRIDE WG THALIDOMIDE MAY BE A MUTAGEN | 16 | 22 |
350 | 3 | 6 | 1207 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(5):837-838 BERGER TG; HOFFMAN C; THIEBERG MD PRURIGO NODULARIS AND PHOTOSENSITIVITY IN AIDS - TREATMENT WITH THALIDOMIDE | 13 | 22 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
351 | 8 | 53 | 1894 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(4):881-894 Zorat F; Shetty V; Dutt D; Lisak L; Nascimben F; Allampallam K; Dar S; York A; Gezer S; Venugopal P; Raza A The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes | 13 | 22 |
352 | 6 | 12 | 293 1964 NATURE 201(492):1125-& FABRO S; SCHUMACHER H; SMITH RL; WILLIAMS RT IDENTIFICATION OF THALIDOMIDE IN RABBIT BLASTOCYSTS | 11 | 21 |
353 | 4 | 7 | 585 1973 TERATOLOGY 8(2):163-166 KAJII T; KIDA M; TAKAHASH.K EFFECT OF THALIDOMIDE INTAKE DURING 113 HUMAN PREGNANCIES | 8 | 21 |
354 | 9 | 21 | 590 1974 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 24(10):1616-1619 KOHLER F; KOCH H TERATOLOGY STUDY ON THALIDOMIDE-LIKE COMPOUNDS K-2004 AND K-2604 IN MOUSE AND RAT | 9 | 21 |
355 | 6 | 25 | 774 1982 ARCHIVES OF DERMATOLOGICAL RESEARCH 274(3-4):363-367 MIYACHI Y; OZAKI M; UCHIDA K; NIWA Y EFFECTS OF THALIDOMIDE ON THE GENERATION OF OXYGEN INTERMEDIATES BY ZYMOSAN-STIMULATED NORMAL POLYMORPHONUCLEAR LEUKOCYTES | 13 | 21 |
356 | 3 | 17 | 799 1983 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 110(8):611-614 MOULIN G; BONNET F; BARRUT D; FRANC MP TREATMENT OF JESSNER-KANOF DISEASE WITH THALIDOMIDE | 12 | 21 |
357 | 3 | 46 | 959 1988 ARCHIVES OF TOXICOLOGY 61(3):180-191 NEUBERT D; HEGER W; MERKER HJ; SAMES K; MEISTER R EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .2. ELUCIDATION OF THE SUSCEPTIBLE PERIOD AND OF THE VARIABILITY OF EMBRYONIC STAGES | 8 | 21 |
358 | 2 | 2 | 974 1988 LANCET 2(8620):1135-1135 MCCARTHY DM; KANFER E; TAYLOR J; BARRETT AJ THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 19 | 21 |
359 | 63 | 106 | 1003 1990 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 117(4):313-321 REVUZ J THALIDOMIDE | 16 | 21 |
360 | 0 | 6 | 1014 1990 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 263(11):1467-1468 RANDALL T THALIDOMIDE BACK IN THE NEWS, BUT IN MORE FAVORABLE CIRCUMSTANCES | 7 | 21 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
361 | 4 | 10 | 1061 1992 JOURNAL OF INFECTIOUS DISEASES 166(4):939-940 GEORGHIOU PR; ALLWORTH AM THALIDOMIDE IN PAINFUL AIDS-ASSOCIATED PROCTITIS | 11 | 21 |
362 | 20 | 52 | 1192 1995 EXPERIMENTAL HEMATOLOGY 23(9):978-985 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION | 21 | 21 |
363 | 12 | 14 | 1453 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 38(3):490-491 Hecker MS; Lebwohl MG Recalcitrant pyoderma gangrenosum: Treatment with thalidomide | 14 | 21 |
364 | 13 | 23 | 1569 1999 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 28(2):214-216 Weinstein TA; Sciubba JJ; Levine J Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease | 10 | 21 |
365 | 20 | 25 | 1735 2000 JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 21 | 21 |
366 | 3 | 19 | 1878 2001 BLOOD 98(13):3846-3848 Moehler TM; Neben K; Benner A; Egerer G; Krasniqi F; Ho AD; Goldschmidt H Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy | 13 | 21 |
367 | 17 | 33 | 1938 2001 HAEMATOLOGICA 86(4):409-413 Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation | 13 | 21 |
368 | 7 | 28 | 2030 2002 ANNALS OF ONCOLOGY 13(7):1029-1035 Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A Phase II trial of thalidomide in renal-cell carcinoma | 10 | 21 |
369 | 12 | 36 | 2136 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296 Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia | 12 | 21 |
370 | 15 | 28 | 184 1963 ACTA PHARMACOLOGICA ET TOXICOLOGICA 20(3):186-& LARSEN V TERATOGENIC EFFECTS OF THALIDOMIDE, IMIPRAMINE HCL AND IMIPRAMINE-N-OXIDE HCL ON WHITE DANISH RABBITS | 5 | 20 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
371 | 7 | 23 | 397 1966 LANCET 1(7447):1136-& HELLMANN K IMMUNOSUPPRESSION BY THALIDOMIDE - IMPLICATIONS FOR TERATOLOGY | 14 | 20 |
372 | 6 | 15 | 422 1967 BIOCHEMICAL JOURNAL 104(2):565-& FABRO S; SMITH RL; WILLIAMS RT FATE OF [14C]THALIDOMIDE IN PREGNANT RABBIT | 17 | 20 |
373 | 2 | 7 | 425 1967 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 48(1):107-& VICKERS TH THALIDOMIDE EMBRYOPATHY IN HYBRID RABBITS | 8 | 20 |
374 | 15 | 31 | 449 1968 ARCHIVES OF ENVIRONMENTAL HEALTH 16(4):493-& WILLIAMS RT THALIDOMIDE - A STUDY OF BIOCHEMICAL TERATOLOGY | 9 | 20 |
375 | 16 | 29 | 477 1969 ARZNEIMITTEL-FORSCHUNG 19(2):167-& STOCKING.L; KOCH H TERATOLOGY STUDY ON A NEW COMPOUND (K-2004) WITH SEDATIVE-HYPNOTIC ACTIVITY AND STRUCTURALLY RELATED TO THALIDOMIDE | 0 | 20 |
376 | 6 | 12 | 505 1970 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 173(2):265-& SCHUMACHER HJ; WILSON JG; TERAPANE JF; ROSEDALE SL THALIDOMIDE - DISPOSITION IN RHESUS MONKEY AND STUDIES OF ITS HYDROLYSIS IN TISSUES OF THIS AND OTHER SPECIES | 18 | 20 |
377 | 13 | 27 | 915 1986 BRITISH JOURNAL OF DERMATOLOGY 115(3):367-370 RAMSELAAR CG; BOONE RM; KLUINNELEMANS HC THALIDOMIDE IN THE TREATMENT OF NEURO-BEHCETS SYNDROME | 10 | 20 |
378 | 1 | 20 | 1048 1991 LEUKEMIA RESEARCH 15(2-3):129-136 HATFILL SJ; FESTER ED; DEBEER DP; BOHM L INDUCTION OF MORPHOLOGICAL-DIFFERENTIATION IN THE HUMAN LEUKEMIC-CELL LINE K562 BY EXPOSURE TO THALIDOMIDE METABOLITES | 17 | 20 |
379 | 4 | 4 | 1179 1995 BRITISH JOURNAL OF DERMATOLOGY 132(1):168-168 MEUNIER L; MARCK Y; RIBEYRE C; MEYNADIER J ADULT CUTANEOUS LANGERHANS CELL HISTIOCYTOSIS - REMISSION WITH THALIDOMIDE TREATMENT | 9 | 20 |
380 | 7 | 14 | 1245 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 226(2):439-444 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence | 13 | 20 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
381 | 0 | 0 | 1414 1998 BLOOD 92(10):318A-318A Singhal S; Mehta J; Eddlemon P; Gray P; Cromer J; Desikan R; Ayers D; Siegel D; Munshi N; Anaissie E; Kantarjian H; Zeldis J; Barlogie B Marked anti-tumor effect from anti-angiogenesis (AA) therapy with thalidomide (T) in high risk refractory multiple myeloma (MM). | 0 | 20 |
382 | 3 | 9 | 1467 1998 NATURE 396(6709):322-323 Tabin CJ A developmental model for thalidomide defects | 9 | 20 |
383 | 10 | 18 | 1560 1999 JOURNAL OF CHROMATOGRAPHY B 723(1-2):255-264 Meyring M; Strickmann D; Chankvetadze B; Blaschke G; Desiderio C; Fanali S Investigation of the in vitro biotransformation of R-(+)- thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS | 8 | 20 |
384 | 24 | 45 | 1688 2000 CANCER CHEMOTHERAPY AND PHARMACOLOGY 46(2):135-141 Kestell P; Zhao LL; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide | 6 | 20 |
385 | 8 | 38 | 1779 2000 PAIN 88(3):267-275 George A; Marziniak M; Schafers M; Toyka KV; Sommer C Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin | 4 | 20 |
386 | 9 | 23 | 1966 2001 JOURNAL OF NEURO-ONCOLOGY 51(1):41-45 Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M Thalidomide as an anti-angiogenic agent in relapsed gliomas | 10 | 20 |
387 | 7 | 29 | 1967 2001 JOURNAL OF NEURO-ONCOLOGY 54(1):31-38 Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme | 13 | 20 |
388 | 54 | 61 | 2043 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 16 | 20 |
389 | 23 | 39 | 2532 2003 MAYO CLINIC PROCEEDINGS 78(1):34-39 Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma | 9 | 20 |
390 | 0 | 0 | 14 1961 BRITISH MEDICAL JOURNAL 1(521):130-& BURLEY D IS THALIDOMIDE TO BLAME | 17 | 19 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
391 | 0 | 0 | 116 1962 LANCET 1(7223):271-& BURLEY DM THALIDOMIDE AND CONGENITAL ABNORMALITIES | 13 | 19 |
392 | 6 | 14 | 355 1965 TOXICOLOGY AND APPLIED PHARMACOLOGY 7(2):165-& DROBECK HP; COULSTON F; CORNELIU.D EFFECTS OF THALIDOMIDE ON FETAL DEVELOPMENT IN RABBITS AND ON ESTABLISHMENT OF PREGNANCY IN MONKEYS | 5 | 19 |
393 | 8 | 24 | 583 1973 TERATOLOGY 7(2):151-& HENDRICK.AG; NEWMAN L APPENDICULAR SKELETAL AND VISCERAL MALFORMATIONS INDUCED BY THALIDOMIDE IN BONNET MONKEYS | 0 | 19 |
394 | 11 | 35 | 918 1986 CLINICS IN PERINATOLOGY 13(3):555-573 NEWMAN CGH THE THALIDOMIDE SYNDROME - RISKS OF EXPOSURE AND SPECTRUM OF MALFORMATIONS | 6 | 19 |
395 | 5 | 17 | 966 1988 CLINICAL AND EXPERIMENTAL DERMATOLOGY 13(6):408-410 MUNRO CS; COX NH PYODERMA GANGRENOSUM ASSOCIATED WITH BEHCETS SYNDROME - RESPONSE TO THALIDOMIDE | 12 | 19 |
396 | 9 | 13 | 1085 1993 ARCHIVES OF DERMATOLOGY 129(12):1548-1550 HOLM AL; BOWERS KE; MCMEEKIN TO; GASPARI AA CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS TREATED WITH THALIDOMIDE | 16 | 19 |
397 | 0 | 12 | 1136 1994 CHIRALITY 6(4):221-224 KNOCHE B; BLASCHKE G STEREOSELECTIVITY OF THE IN-VITRO METABOLISM OF THALIDOMIDE | 15 | 19 |
398 | 6 | 23 | 1212 1995 MICROBIAL PATHOGENESIS 19(4):245-255 BURROUGHS MH; TSENOVABERKOVA L; SOKOL K; OSSIG J; TUOMANEN E; KAPLAN G EFFECT OF THALIDOMIDE ON THE INFLAMMATORY RESPONSE IN CEREBROSPINAL-FLUID IN EXPERIMENTAL BACTERIAL-MENINGITIS | 10 | 19 |
399 | 7 | 18 | 1222 1995 TETRAHEDRON-ASYMMETRY 6(6):1249-1252 ROBIN S; ZHU J; GALONS H; PHAMHUY C; CLAUDE JR; TOMAS A; VIOSSAT B A CONVENIENT ASYMMETRIC-SYNTHESIS OF THALIDOMIDE | 8 | 19 |
400 | 2 | 14 | 1261 1996 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 8(9):929-931 Postema PTE; denHaan P; vanHagen PM; vanBlankenstein M Treatment of colitis in Behcet's disease with thalidomide | 12 | 19 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
401 | 5 | 19 | 1397 1998 ANNALS OF INTERNAL MEDICINE 128(6):494-495 Ehrlich GE Behcet disease and the emergence of thalidomide | 4 | 19 |
402 | 7 | 13 | 1404 1998 ARTHRITIS AND RHEUMATISM 41(12):2273-2275 Ordi J; Cortes F; Martinez N; Mauri M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease | 12 | 19 |
403 | 12 | 15 | 1562 1999 JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
404 | 4 | 9 | 1721 2000 HAEMATOLOGICA 85(10):1111-1112 Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A Low-dose thalidomide in the treatment of refractory myeloma | 11 | 19 |
405 | 5 | 12 | 1887 2001 BRITISH JOURNAL OF HAEMATOLOGY 113(2):422-424 Blade J; Perales M; Rosinol L; Tuset M; Montoto S; Esteve O; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas | 18 | 19 |
406 | 4 | 20 | 2060 2002 BLOOD 100(6):2263-2265 Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Opelz G; Goldschmidt H Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma | 9 | 19 |
407 | 1 | 5 | 237 1963 LANCET 1(728):1003-& PLAYFAIR JH; DAVIES AJS; LEUCHARS E EFFECT OF THALIDOMIDE ON SKIN-GRAFT SURVIVAL | 0 | 18 |
408 | 7 | 18 | 269 1964 ANATOMICAL RECORD 149(1):149-& DIPAOLO JA; PICKREN J; GATZEK H MALFORMATIONS INDUCED IN MOUSE BY THALIDOMIDE | 9 | 18 |
409 | 1 | 6 | 359 1966 ACTA OPHTHALMOLOGICA 44(3):391-& ZETTERST.B OCULAR MALFORMATIONS CAUSED BY THALIDOMIDE | 0 | 18 |
410 | 10 | 19 | 398 1966 LANCET 1(7449):1240-& BORE PJ; SCOTHORN.RJ EFFECT OF THALIDOMIDE ON SURVIVAL OF SKIN HOMOGRAFTS IN RABBITS | 16 | 18 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
411 | 5 | 8 | 427 1967 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 48(6):579-& VICKERS TH CONCERNING MORPHOGENESIS OF THALIDOMIDE DYSMELIA IN RABBITS | 12 | 18 |
412 | 3 | 28 | 472 1968 TERATOLOGY 1(3):235-& GLOBUS M; GIBSON MA A HISTOLOGICAL AND HISTOCHEMICAL STUDY OF DEVELOPMENT OF STERNUM IN THALIDOMIDE-TREATED RATS | 6 | 18 |
413 | 2 | 53 | 524 1971 FORTSCHRITTE DER NEUROLOGIE UND PSYCHIATRIE UND IHRER GRENZGEBIETE 39(1):15-& KRUCKE W; HARTROTT HH; SCHRODER JM; THOMAS E; GIBBELS E; SCHEID W LIGHT AND ELECTRON MICROSCOPIC STUDIES ON LATE STAGE OF THALIDOMIDE POLYNEUROPATHY | 13 | 18 |
414 | 2 | 7 | 528 1971 NATURE 232(5313):634-& LASH JW; SAXEN L EFFECT OF THALIDOMIDE ON HUMAN EMBRYONIC TISSUES | 7 | 18 |
415 | 0 | 18 | 611 1975 FOOD AND COSMETICS TOXICOLOGY 13(1):55-61 KENNEDY GL; ARNOLD DW; KEPLINGER ML MUTAGENICITY STUDIES WITH CAPTAN, CAPTOFOL, FOLPET AND THALIDOMIDE | 0 | 18 |
416 | 10 | 11 | 948 1987 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 64(3):289-292 EISENBUD L; HOROWITZ I; KAY B RECURRENT APHTHOUS STOMATITIS OF THE BEHCETS TYPE - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 7 | 18 |
417 | 15 | 59 | 958 1988 ARCHIVES OF TOXICOLOGY 61(3):165-179 MERKER HJ; HEGER W; SAMES K; STURJE H; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE-DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .1. EFFECTS OF 3-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-2,6-DIOXOPIPERIDINE (EM-12) ON SKELETAL DEVELOPMENT | 10 | 18 |
418 | 3 | 11 | 960 1988 ARCHIVES OF TOXICOLOGY 62(2-3):200-204 SCHMAHL HJ; NAU H; NEUBERT D THE ENANTIOMERS OF THE TERATOGENIC THALIDOMIDE ANALOG EM-12 .1. CHIRAL INVERSION AND PLASMA PHARMACOKINETICS IN THE MARMOSET MONKEY | 8 | 18 |
419 | 1 | 6 | 1052 1992 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 119(4):281-283 BENSAID P; MACHET L; VAILLANT L; MACHET MC; SCOTTO B; LORETTE G ADULT LANGERHANS-CELL HISTIOCYTOSIS - REGRESSION OF PAROTID-GLAND INVOLVEMENT AFTER THALIDOMIDE TREATMENT | 13 | 18 |
420 | 3 | 5 | 1064 1992 LANCET 339(8789):365-365 WINTER W; FRANKUS E THALIDOMIDE ENANTIOMERS | 12 | 18 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
421 | 3 | 3 | 1094 1993 CLINICAL AND EXPERIMENTAL DERMATOLOGY 18(5):487-487 MISERY L; LARBRE B; LYONNET S; FAURE M; THIVOLET J REMISSION OF LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE TREATMENT | 11 | 18 |
422 | 12 | 24 | 1169 1995 ANNALS OF THORACIC SURGERY 59(2):277-282 UTHOFF K; ZEHR KJ; GAUDIN PB; KUMAR P; CHO PW; VOGELSANG G; HRUBAN RH; BAUMGARTNER WA; STUART RS THALIDOMIDE AS REPLACEMENT FOR STEROIDS IN IMMUNOSUPPRESSION AFTER LUNG TRANSPLANTATION | 16 | 18 |
423 | 7 | 23 | 1174 1995 BIOLOGICAL & PHARMACEUTICAL BULLETIN 18(9):1228-1233 SASAKI K; SHIBATA Y; HASHIMOTO Y; IWASAKI S BENZYLPHTHALIMIDES AND PHENETHYLPHTHALIMIDES WITH THALIDOMIDE-LIKE ACTIVITY ON THE PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA | 7 | 18 |
424 | 13 | 28 | 1252 1996 CHIRALITY 8(1):11-17 Reepmeyer JC Separation of R-and S-thalidomide by reversed-phase HPLC with beta-cyclodextrin in the mobile phase | 6 | 18 |
425 | 12 | 21 | 1340 1997 IMMUNOPHARMACOLOGY 36(1):9-15 Shannon EJ; Sandoval F; Krahenbuhl JL Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha | 17 | 18 |
426 | 30 | 79 | 1487 1999 ANNALS OF THE RHEUMATIC DISEASES 58:107-113 Corral LG; Kaplan G Immunomodulation by thalidomide and thalidomide analogues | 13 | 18 |
427 | 0 | 0 | 1512 1999 BLOOD 94(10):316A-316A Durie BGM; Stepan DE Efficacy of low dose thalidomide (T) in multiple myeloma. | 0 | 18 |
428 | 8 | 33 | 1693 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 119(1):123-129 La Maestra L; Zaninoni A; Marriott JB; Lazzarin A; Dalgleish AG; Barcellini W The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro | 10 | 18 |
429 | 6 | 26 | 2224 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2610-2615 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial | 10 | 18 |
430 | 12 | 32 | 2516 2003 LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 11 | 18 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
431 | 0 | 0 | 119 1962 LANCET 1(7224):326-& KOHLER HG; FISHER AM; DUNN PM THALIDOMIDE AND CONGENITAL ABNORMALITIES | 7 | 17 |
432 | 11 | 24 | 279 1964 CANADIAN JOURNAL OF BIOCHEMISTRY AND PHYSIOLOGY 42(1):35-& BOYLEN JB; HORNE HH; JOHNSON WJ TERATOGENIC EFFECTS OF THALIDOMIDE + ITS METABOLITES ON DEVELOPING CHICK EMBRYO | 12 | 17 |
433 | 3 | 9 | 423 1967 BIOCHEMICAL JOURNAL 104(2):570-& FABRO S; SMITH RL; WILLIAMS RT FATE OF HYDROLYSIS PRODUCTS OF THALIDOMIDE IN PREGNANT RABBIT | 14 | 17 |
434 | 5 | 22 | 500 1970 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 7(2):241-& COULSON AS; SUMMERS LJ; LINDAHLK.K; TUCKER D; HELLMANN K EFFECT OF 2 SOLUBLE THALIDOMIDE DERIVATIVES ON LYMPHOCYTE STIMULATION | 16 | 17 |
435 | 7 | 13 | 523 1971 EXPERIENTIA 27(10):1149-& KOHLER F; MEISE W; OCKENFEL.H TERATOLOGICAL TESTING OF SOME THALIDOMIDE METABOLITES | 6 | 17 |
436 | 7 | 24 | 648 1977 JOURNAL OF EMBRYOLOGY AND EXPERIMENTAL MORPHOLOGY 41(OCT):125-135 BAZZOLI AS; MANSON J; SCOTT WJ; WILSON JG EFFECTS OF THALIDOMIDE AND 2 ANALOGS ON REGENERATING FORELIMB OF NEWT | 4 | 17 |
437 | 3 | 9 | 697 1979 HAUTARZT 30(7):376-379 SHESKIN J; YAAR I MOTOR CONDUCTIVITY OF CUBITAL NERVES IN PATIENTS WITH LEPRA REACTION - EXPERIENCE OF 13 YEARS DURING THALIDOMIDE-TREATMENT | 15 | 17 |
438 | 5 | 8 | 742 1981 ARCHIVES OF DERMATOLOGICAL RESEARCH 271(2):165-170 KNOP J; HAPPLE R; BONSMANN G; VAKILZADEH F; MACHER E TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 16 | 17 |
439 | 15 | 23 | 989 1989 BIOMEDICINE & PHARMACOTHERAPY 43(9):693-697 MCCARTHY DM; KANFER EJ; BARRETT AJ THALIDOMIDE FOR THE THERAPY OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION | 15 | 17 |
440 | 7 | 15 | 1001 1989 TOXICOLOGY LETTERS 45(1):23-33 SCHMAHL HJ; HEGER W; NAU H THE ENANTIOMERS OF THE TERATOGENIC THALIDOMIDE ANALOG EM-12 .2. CHEMICAL-STABILITY, STEREOSELECTIVITY OF METABOLISM AND RENAL EXCRETION IN THE MARMOSET MONKEY | 7 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
441 | 6 | 13 | 1010 1990 DICP-THE ANNALS OF PHARMACOTHERAPY 24(11):1054-1056 NICOLAU DP; WEST TE THALIDOMIDE - TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN PATIENTS WITH AIDS | 9 | 17 |
442 | 1 | 6 | 1046 1991 JOURNAL OF LIQUID CHROMATOGRAPHY 14(4):667-673 ABOULENEIN HY; ISLAM MR DIRECT HPLC SEPARATION OF THALIDOMIDE ENANTIOMERS USING CELLULOSE TRIS-4-METHYLPHENYL BENZOATE CHIRAL STATIONARY PHASE | 9 | 17 |
443 | 18 | 22 | 1138 1994 DERMATOLOGY 189(2):179-181 BIELSA I; TEIXIDO J; RIBERA M; FERRANDIZ C ERYTHRODERMA DUE TO THALIDOMIDE - REPORT OF 2 CASES | 13 | 17 |
444 | 11 | 14 | 1168 1995 ANNALS OF CLINICAL BIOCHEMISTRY 32:79-83 BOUGHTON BJ; SHEEHAN TMT; WOOD J; OBRIEN D; BUTLER M; SIMPSON A; HALE KA HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF PLASMA THALIDOMIDE - STABILIZATION OF SPECIMENS AND DETERMINATION OF A TENTATIVE THERAPEUTIC RANGE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 17 | 17 |
445 | 9 | 19 | 1171 1995 ARCHIVES OF DERMATOLOGY 131(9):1032-1035 GUILLAUME JC; MOULIN G; DIENG MT; POLI F; MOREL P; SOUTEYRAND P; BONNETBLANC JM; CLAUDY A; DANIEL F; VAILLANT L; BERNARD P; BOUILLIE MC; BOURNERIAS I; DENOEUX JP; LAMBERT D; LEONARD F; CHAUMEIL JC; REVUZ J CROSSOVER STUDY OF THALIDOMIDE VS PLACEBO IN JESSNERS LYMPHOCYTIC INFILTRATION OF THE SKIN | 12 | 17 |
446 | 10 | 20 | 1281 1996 JOURNAL OF SURGICAL RESEARCH 63(1):143-146 Schmidt H; Rush B; Simonian G; Murphy T; Hsieh J; Condon M Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats | 8 | 17 |
447 | 8 | 17 | 1298 1996 TERATOLOGY 54(6):273-277 Castilla EE; AshtonProlla P; BarredaMejia E; Brunoni D; Cavalcanti DP; CorreaNeto J; Delgadillo JL; Dutra MG; Felix T; Giraldo A; Juarez N; LopezCamelo JS; Nazer J; Orioli IM; Paz JE; Pessoto MA; PinaNeto JM; Quadrelli R; Rittler M; Rueda S; Saltos M; Sanchez O; Schuler L Thalidomide, a current teratogen in South America | 14 | 17 |
448 | 18 | 41 | 1422 1998 CHEMICAL RESEARCH IN TOXICOLOGY 11(12):1521-1528 Reist M; Carrupt PA; Francotte E; Testa B Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites | 15 | 17 |
449 | 79 | 87 | 1478 1998 SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 17(4):231-242 Stirling DI Thalidomide and its impact in dermatology | 14 | 17 |
450 | 11 | 15 | 1571 1999 JOURNAL OF RHEUMATOLOGY 26(11):2344-2347 Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC Thalidomide in the treatment of refractory rheumatoid arthritis | 14 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
451 | 17 | 32 | 1623 2000 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 16 | 17 |
452 | 9 | 19 | 1680 2000 BONE MARROW TRANSPLANTATION 26(8):865-869 Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NKC; Wagner J; Enright H Response to thalidomide therapy in refractory chronic graft-versus-host disease | 11 | 17 |
453 | 16 | 22 | 1727 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(3):218-222 Kyriakis KP; Kontochristopoulos GJ; Panteleos DN Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus | 10 | 17 |
454 | 28 | 36 | 1750 2000 JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
455 | 14 | 57 | 1774 2000 ONCOLOGY-NEW YORK 14(12):11-16 Rajkumar SV Thalidomide in multiple myeloma | 9 | 17 |
456 | 28 | 123 | 1912 2001 CURRENT OPINION IN ONCOLOGY 13(5):374-381 Krown SE Management of Kaposi sarcoma: the role of interferon and thalidomide | 2 | 17 |
457 | 11 | 18 | 1969 2001 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 32(2):178-181 Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results | 10 | 17 |
458 | 8 | 18 | 2006 2001 SEMINARS IN ONCOLOGY 28(6):577-582 Barlogie B; Tricot G; Anaissie E Thalidomide in the management of multiple myeloma | 10 | 17 |
459 | 5 | 5 | 2054 2002 BLOOD 99(11):4247-4248 Urbauer E; Kaufmann H; Nosslinger T; Raderer M; Drach J Thromboembolic events during treatment with thalidomide | 12 | 17 |
460 | 33 | 37 | 2157 2002 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(1):75-84 Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells | 15 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
461 | 0 | 0 | 120 1962 LANCET 1(7226):429-& RUSSELL CS; MCKICHAN MD THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 16 |
462 | 1 | 34 | 144 1962 LANCET 2(7256):599-& MILLEN JW THALIDOMIDE AND LIMB DEFORMITIES | 0 | 16 |
463 | 4 | 12 | 327 1965 CHEMISTRY & INDUSTRY (24):1030-& SHEALY YF; OPLIGER CE; MONTGOME.JA D-AND 6-THALIDOMIDE | 0 | 16 |
464 | 8 | 14 | 358 1965 TOXICOLOGY AND APPLIED PHARMACOLOGY 7(5):686-& HOMBURGE.F; CHAUBE S; EPPENBER.M; BOGDONOF.PD; NIXON CW SUSCEPTIBILITY OF CERTAIN INBRED STRAINS OF HAMSTERS TO TERATOGENIC EFFECTS OF THALIDOMIDE | 0 | 16 |
465 | 6 | 27 | 468 1968 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 161(2):348-& BAKAY B; NYHAN WL BINDING THALIDOMIDE BY MACROMOLECULES IN FETAL AND MATERNAL RAT | 11 | 16 |
466 | 0 | 24 | 687 1978 TERATOLOGY 18(3):393-403 HENDRICKX AG; SAWYER RH DEVELOPMENTAL STAGING AND THALIDOMIDE TERATOGENICITY IN GREEN MONKEY (CERCOPITHECUS-AETHIOPS) | 3 | 16 |
467 | 5 | 20 | 746 1981 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 98(4):1029-1034 BRAUN AG; DAILEY JP THALIDOMIDE METABOLITE INHIBITS TUMOR-CELL ATTACHMENT TO CONCANAVALIN A COATED SURFACES | 6 | 16 |
468 | 1 | 2 | 830 1983 PRESSE MEDICALE 12(15):963-963 BARRIERE H SARCOIDOSIS OF THE SKIN - TREATMENT WITH THALIDOMIDE | 12 | 16 |
469 | 3 | 17 | 850 1984 DERMATOLOGICA 168(4):182-188 GENVO MF; FAURE M; THIVOLET J THALIDOMIDE AND THALIDOMIDE WITH COLCHICINE IN THE TREATMENT OF APHTHOSIS, RECURRENT MUCOCUTANEOUS APHTHAE AND BEHCETS-DISEASE | 8 | 16 |
470 | 2 | 2 | 879 1985 BRITISH JOURNAL OF DERMATOLOGY 112(5):632-632 KURKCUOGLU N; ATAKAN N; EKSIOGLU M THALIDOMIDE IN THE TREATMENT OF RECURRENT NECROTIC MUCOCUTANEOUS APHTHAE | 13 | 16 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
471 | 4 | 8 | 985 1988 TRANSPLANTATION PROCEEDINGS 20(2):226-228 VOGELSANG GB; WELLS MC; SANTOS GW; CHEN TL; HESS AD COMBINATION LOW-DOSE THALIDOMIDE AND CYCLOSPORINE PROPHYLAXIS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN A RAT MISMATCHED MODEL | 14 | 16 |
472 | 6 | 13 | 1063 1992 JOURNAL OF PHARMACEUTICAL SCIENCES 81(7):685-689 KRENN M; GAMCSIK MP; VOGELSANG GB; COLVIN OM; LEONG KW IMPROVEMENTS IN SOLUBILITY AND STABILITY OF THALIDOMIDE UPON COMPLEXATION WITH HYDROXYPROPYL-BETA-CYCLODEXTRIN | 9 | 16 |
473 | 5 | 9 | 1372 1997 NATURE 385(6614):303-304 Wnendt S; Zwingenberger K Thalidomide's chirality | 9 | 16 |
474 | 1 | 30 | 1457 1998 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
475 | 8 | 26 | 1498 1999 BIOLOGICAL & PHARMACEUTICAL BULLETIN 22(2):224-226 Shimazawa R; Miyachi H; Takayama H; Kuroda K; Kato F; Kato M; Hashimoto Y Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide | 10 | 16 |
476 | 10 | 22 | 1595 1999 PEDIATRICS 103(6):1295-1297 Shek LPC; Lee YS; Lee BW; Lehman TJA Thalidomide responsiveness in an infant with Behcet's syndrome | 10 | 16 |
477 | 84 | 136 | 1604 1999 TERATOLOGY 60(5):306-321 Miller MT; Stromland K Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses | 5 | 16 |
478 | 17 | 32 | 1708 2000 ELECTROPHORESIS 21(15):3270-3279 Meyring M; Muhlenbrock C; Blaschke G Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 7 | 16 |
479 | 10 | 34 | 1711 2000 EUROPEAN JOURNAL OF PHARMACOLOGY 391(1-2):97-103 Ribeiro RA; Vale ML; Ferreira SH; Cunha FQ Analgesic effect of thalidomide on inflammatory pain | 3 | 16 |
480 | 52 | 73 | 1822 2001 BIODRUGS 15(3):163-172 Singhal S; Mehta J Thalidomide in cancer - Potential uses and limitations | 12 | 16 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
481 | 2 | 12 | 1891 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(2):313-315 Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M Thalidomide in agnogenic and secondary myelofibrosis | 11 | 16 |
482 | 18 | 29 | 1980 2001 MUSCLE & NERVE 24(8):1050-1057 Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD Thalidomide neuropathy in patients treated for metastatic prostate cancer | 11 | 16 |
483 | 4 | 12 | 2415 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(5):768-771 Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma | 11 | 16 |
484 | 8 | 17 | 2515 2003 LEUKEMIA 17(1):41-44 Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo | 7 | 16 |
485 | 1 | 7 | 9 1960 JOURNAL OF PHARMACY AND PHARMACOLOGY 12:T153-T158 MARTINDALE K; SOMERS GF; WILSON CWM THE EFFECT OF THALIDOMIDE IN EXPERIMENTAL GASTRIC ULCERS | 0 | 15 |
486 | 2 | 4 | 179 1962 SCIENTIFIC AMERICAN 207(2):29-& TAUSSIG HB THALIDOMIDE SYNDROME | 7 | 15 |
487 | 4 | 4 | 272 1964 BIOCHEMICAL JOURNAL 90(1):P5-& FABRO S; SCHUMACHER H; STAGG BL; SMITH RL; WILLIAMS RT BIOLOGICAL ACTIVITY OF THALIDOMIDE METABOLITES | 11 | 15 |
488 | 5 | 5 | 278 1964 BULLETIN OF THE JOHNS HOPKINS HOSPITAL 115(3):223-& DEKKER A; MEHRIZI A USE OF THALIDOMIDE AS TERATOGENIC AGENT IN RABBITS | 9 | 15 |
489 | 1 | 8 | 300 1964 PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 116(2):512-& KORANSKY W; ULLBERG S AUTORADIOGRAPHIC INVESTIGATIONS OF 14C-LABELLED THALIDOMIDE + GLUTETHIMIDE IN PREGNANT MICE | 5 | 15 |
490 | 0 | 31 | 492 1970 ACTA GENETICAE MEDICAE ET GEMELLOLOGIAE 19(1-2):205-& JORGENSE.G; LENZ W; PFEIFFER RA; SCHAAFHA.C THALIDOMIDE-EMBRYOPATHY IN TWINS - A COLLABORATIVE STUDY | 0 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
491 | 8 | 17 | 568 1973 EXPERIENTIA 29(4):423-424 MEISE W; OCKENFEL.H; KOHLER F TERATOLOGICAL TESTING OF HYDROLYTIC PRODUCTS OF THALIDOMIDE | 9 | 15 |
492 | 0 | 13 | 737 1980 TERATOLOGY 22(2):179-182 HENDRICKX AG; HELM FC NON-TERATOGENICITY OF A STRUCTURAL ANALOG OF THALIDOMIDE IN PREGNANT BABOONS (PAPIO-CYNOCEPHALUS) | 7 | 15 |
493 | 1 | 5 | 786 1982 NOUVELLE PRESSE MEDICALE 11(14):1080-1081 HAMZA M; CHAFFAI M; BENAYED H TREATMENT OF BEHCETS-DISEASE WITH THALIDOMIDE | 9 | 15 |
494 | 6 | 12 | 907 1985 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 5(3):149-158 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - SPONTANEOUS DECAY PRODUCTS OF THALIDOMIDE AND THALIDOMIDE ANALOGS ARE NOT BIOACTIVATED BY LIVER-MICROSOMES | 11 | 15 |
495 | 9 | 25 | 1117 1994 ARCHIVES OF DERMATOLOGICAL RESEARCH 286(6):347-349 TSAMBAOS D; BOLSEN K; GEORGIOU S; MONASTIRLI A; GOERZ G EFFECTS OF ORAL THALIDOMIDE ON RAT-LIVER AND SKIN MICROSOMAL P450 ISOZYME ACTIVITIES AND ON URINARY PORPHYRIN EXCRETION - INTERACTION WITH ORAL HEXACHLOROBENZENE | 14 | 15 |
496 | 7 | 20 | 1164 1994 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 14(3):115-122 HEGER W; SCHMAHL HJ; KLUG S; FELIES A; NAU H; MERKER HJ; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NONHUMAN PRIMATE CALLITHRIX-JACCHUS .4. TERATOGENICITY OF MU-G/KG DOSES OF THE EM12 ENANTIOMERS | 7 | 15 |
497 | 23 | 76 | 1280 1996 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 277(3):1649-1658 Arlen RR; Wells PG Inhibition of thalidomide teratogenicity by acetylsalicylic acid: Evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate | 9 | 15 |
498 | 9 | 27 | 1429 1998 CLINICAL PHARMACOLOGY & THERAPEUTICS 64(6):597-602 Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone | 13 | 15 |
499 | 16 | 33 | 1450 1998 JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 26(4):363-383 Hoglund P; Eriksson T; Bjorkman S A double-blind study of the sedative effects of the thalidomide enantiomers in humans | 11 | 15 |
500 | 0 | 0 | 1520 1999 BLOOD 94(10):702A-702A Thomas DA; Aguayo A; Giles FJ; Albitar M; O'Brien S; Cortes J; Faderl S; Bivins C; Zeldis J; Keating MJ; Barlogie B; Kantarjian HM Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF). | 0 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
501 | 12 | 70 | 1536 1999 DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
502 | 13 | 49 | 1696 2000 CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
503 | 1 | 1 | 1766 2000 NEW ENGLAND JOURNAL OF MEDICINE 342(5):364-364 Singhal S Antitumor activity of thalidomide in refractory multiple myeloma (vol 341, pg 1565, 1999) | 7 | 15 |
504 | 4 | 12 | 1775 2000 ONCOLOGY-NEW YORK 14(12):17-20 Eisen TG Thalidomide in solid tumors: The London experience | 11 | 15 |
505 | 4 | 18 | 1824 2001 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 7(5):265-273 Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WF; Weisdorf DJ Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease | 8 | 15 |
506 | 44 | 53 | 1925 2001 EXPERT OPINION ON BIOLOGICAL THERAPY 1(4):675-682 Marriott JB; Muller G; Stirling D; Dalgleish AG Immunotherapeutic and antitumour potential of thalidomide analogues | 11 | 15 |
507 | 8 | 8 | 2061 2002 BLOOD 100(6):2272-2273 Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdre L; Palareti G; Masini L; Tura S; Baccarani M Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy | 11 | 15 |
508 | 10 | 36 | 2134 2002 BRITISH JOURNAL OF CANCER 87(10):1166-1172 Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | 9 | 15 |
509 | 19 | 50 | 2412 2003 BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 12 | 15 |
510 | 0 | 0 | 123 1962 LANCET 1(7231):691-& FERGUSON AW THALIDOMIDE AND CONGENITAL ABNORMALITIES | 11 | 14 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
511 | 2 | 3 | 213 1963 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 256(12):2719-& SALZGEBER B; SALAUN J TERATOGENESE EXPERIMENTALE - MALFORMATIONS DE MEMBRES OBTENUES CHEZ LEMBRYON DE POULET APRES TRAITEMENT PAR LA THALIDOMIDE | 8 | 14 |
512 | 3 | 10 | 459 1968 EXPERIENTIA 24(10):993-& WUEST HM; FOX RR; CRARY DD RELATIONSHIP BETWEEN TERATOGENY AND STRUCTURE IN THALIDOMIDE FIELD | 7 | 14 |
513 | 13 | 34 | 527 1971 MONATSHEFTE FUR CHEMIE 102(2):609-& KOCH H; KOTLAN J; FARKOUH E; LINDNER M THALIDOMIDE ANALOGUES .3. | 8 | 14 |
514 | 2 | 18 | 625 1976 LANCET 1(7960):635-637 GARDNER E; ORAHILLY R NEURAL CREST, LIMB DEVELOPMENT, AND THALIDOMIDE EMBRYOPATHY | 1 | 14 |
515 | 14 | 36 | 826 1983 MEDICAL HYPOTHESES 10(4):437-443 HENDLER SS; MCCARTY MF THALIDOMIDE FOR AUTOIMMUNE-DISEASE | 13 | 14 |
516 | 8 | 28 | 922 1986 FOOD AND DRUG LAW JOURNAL 41(4):458-466 SHERMAN M; STRAUSS S THALIDOMIDE - A 25-YEAR PERSPECTIVE | 4 | 14 |
517 | 3 | 3 | 975 1988 LANCET 2(8623):1317-1317 HENEY D; LEWIS IJ; BAILEY CC THALIDOMIDE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN | 9 | 14 |
518 | 28 | 39 | 1006 1990 BIOMEDICINE & PHARMACOTHERAPY 44(4):199-204 HENEY D; BAILEY CC; LEWIS IJ THALIDOMIDE IN THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 12 | 14 |
519 | 5 | 12 | 1148 1994 LANCET 343(8895):432-433 JAKEMAN P; SMITH WCS THALIDOMIDE IN LEPROSY REACTION | 8 | 14 |
520 | 4 | 5 | 1238 1996 ARCHIVES OF DISEASE IN CHILDHOOD 74(1):64-65 Soler RA; Migliorati C; vanWaes H; Nadal D Thalidomide treatment of mucosal ulcerations in HIV infection | 11 | 14 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
521 | 10 | 13 | 1249 1996 BONE MARROW TRANSPLANTATION 17(2):291-293 Forsyth CJ; Cremer PD; Torzillo P; Iland HJ; Young GAR Thalidomide responsive chronic pulmonary GVHD | 8 | 14 |
522 | 7 | 20 | 1305 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(18):1625-1631 Marriott JB; Cookson S; Carlin E; Youle M; Hawkins DA; Nelson M; Pearson P; Vaughan AN; Gazzard B; Dalgleish AG A double-blind placebo-controlled phase II trial of thalidomide in asymptomatic HIV-positive patients: Clinical tolerance and effect on activation markers and cytokines | 9 | 14 |
523 | 16 | 59 | 1371 1997 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 396(1-2):45-64 Ashby J; Tinwell H; Callander RD; Kimber I; Clay P; Galloway SM; Hill RB; Greenwood SK; Gaulden ME; Ferguson MJ; Vogel E; Nivard M; Parry JM; Williamson J Thalidomide: lack of mutagenic activity across phyla and genetic endpoints | 12 | 14 |
524 | 24 | 35 | 1523 1999 CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
525 | 27 | 52 | 1566 1999 JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 14 |
526 | 0 | 0 | 1576 1999 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
527 | 0 | 0 | 1670 2000 BLOOD 96(11):514A-514A Barlogie B; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 14 |
528 | 7 | 16 | 1776 2000 ONCOLOGY-NEW YORK 14(12):25-28 Hwu WJ New approaches in the treatment of metastatic melanoma: Thalidomide and temozolomide | 6 | 14 |
529 | 34 | 70 | 1990 2001 ONCOLOGY-NEW YORK 15(7):867-874 Rajkumar SV Current status of thalidomide in the treatment of cancer | 9 | 14 |
530 | 14 | 41 | 2002 2001 RHEUMATOLOGY 40(8):933-938 Kari JA; Shah V; Dillon MJ Behcet's disease in UK children: clinical features and treatment including thalidomide | 5 | 14 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
531 | 21 | 36 | 2019 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(6):1117-1124 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 4 | 14 |
532 | 30 | 91 | 2049 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(3):461-479 Hashimoto Y Structural development of biological response modifiers based on thalidomide | 7 | 14 |
533 | 6 | 43 | 2148 2002 CANCER 95(8):1629-1636 Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma | 8 | 14 |
534 | 28 | 54 | 2161 2002 CLINICAL CANCER RESEARCH 8(6):1964-1973 Ando Y; Fuse E; Figg WD Thalidomide metabolism by the CYP2C subfamily | 13 | 14 |
535 | 0 | 0 | 15 1961 BRITISH MEDICAL JOURNAL 1(522):291-& KUENSSBERG EV; STANTON JB; SIMPSON JA IS THALIDOMIDE TO BLAME | 10 | 13 |
536 | 3 | 7 | 88 1962 CANADIAN MEDICAL ASSOCIATION JOURNAL 86(16):744-& RODIN AE; KOLLER LA; TAYLOR JD ASSOCIATION OF THALIDOMIDE (KEVADON) WITH CONGENITAL ANOMALIES | 8 | 13 |
537 | 1 | 3 | 96 1962 COMPTES RENDUS HEBDOMADAIRES DES SEANCES DE L ACADEMIE DES SCIENCES 255(14):1646-& GIROUD A; MERCIERPAROT L; TUCHMANNDUPLESSIS H EMBRYOLOGIE TERATOLOGIQUE - PRODUCTION DE MALFORMATIONS CONGENITALES CHEZ LA SOURIS APRES ADMINISTRATION DE FAIBLES DOSES DE THALIDOMIDE | 2 | 13 |
538 | 0 | 0 | 124 1962 LANCET 1(7231):691-& ROGERSON G THALIDOMIDE AND CONGENITAL ABNORMALITIES - REPLY | 11 | 13 |
539 | 0 | 0 | 235 1963 LANCET 1(728):772-& EHMANN B TERATOGENIC EFFECTS OF THALIDOMIDE | 7 | 13 |
540 | 4 | 8 | 249 1963 NATURE 200(491):1016-& ROE FJC; MITCHLEY BC THALIDOMIDE AND NEOPLASIA | 8 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
541 | 3 | 4 | 296 1964 NEW ENGLAND JOURNAL OF MEDICINE 271(9):441-& INGALLS TH; ZAPPASODI P; CURLEY FJ THALIDOMIDE EMBRYOPATHY IN HYPRID RABBITS | 6 | 13 |
542 | 3 | 10 | 304 1965 ACTA CHEMICA SCANDINAVICA 19(5):1266-& FURBERG S STRUCTURAL RELATIONSHIP BETWEEN THALIDOMIDE AND NUCLEOSIDES | 8 | 13 |
543 | 8 | 29 | 339 1965 JOURNAL OF NUTRITION 85(3):309-& FRIEDMAN L; SHUE GM; HOVE EL RESPONSE OF RATS TO THALIDOMIDE AS AFFECTED BY RIBOFLAVIN OR FOLIC ACID DEFICIENCY | 0 | 13 |
544 | 8 | 13 | 437 1967 LANCET 1(7489):569-& DUKOR P; DIETRICH FM IMMUNOSUPRESSION BY THALIDOMIDE | 10 | 13 |
545 | 15 | 46 | 440 1967 MONATSHEFTE FUR CHEMIE 98(3):702-& KOCH H; KOTLAN J; BRAUN H THALIDOMIDE ANALOGUES .2. | 10 | 13 |
546 | 3 | 15 | 462 1968 ISRAEL JOURNAL OF MEDICAL SCIENCES 4(4):901-& SHESKIN J; SAGHER F; DORFMAN M; VONSCHRA.HW UNSATISFACTORY RESULTS WITH THALIDOMIDE AS A SPECIFIC TREATMENT FOR LEPROSY | 13 | 13 |
547 | 4 | 12 | 655 1977 PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON 70(4):225-227 NEWMAN CGH CLINICAL OBSERVATIONS ON THALIDOMIDE SYNDROME | 0 | 13 |
548 | 0 | 0 | 741 1981 ARCHIVES OF DERMATOLOGICAL RESEARCH 270(2):229-229 KNOP J; HAPPLE R; VAKILZADEH F; MACHER E TREATMENT OF LUPUS-ERYTHEMATOSUS PROFUNDUS WITH THALIDOMIDE | 11 | 13 |
549 | 0 | 3 | 761 1981 PRACTITIONER 225(1355):721-& QUIBELL EP THE THALIDOMIDE EMBRYOPATHY - AN ANALYSIS FROM THE UK | 9 | 13 |
550 | 4 | 40 | 769 1981 TERATOLOGY 23(3):351-364 NEWMAN LM; HENDRICKX AG FETAL EAR MALFORMATIONS INDUCED BY MATERNAL INGESTION OF THALIDOMIDE IN THE BONNET MONKEY (MACACA, RADIATA) | 2 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
551 | 5 | 15 | 961 1988 ARCHIVES OF TOXICOLOGY 62(2-3):205-208 HEGER W; KLUG S; SCHMAHL HJ; NAU H; MERKER HJ; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES ON THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .3. TERATOGENIC POTENCY OF THE EM-12 ENANTIOMERS | 6 | 13 |
552 | 1 | 6 | 1059 1992 INTERNATIONAL JOURNAL OF DERMATOLOGY 31(8):599-600 BERNAL JE; DURAN MM; LONDONO F; UMANA A CELLULAR IMMUNE EFFECTS OF THALIDOMIDE IN ACTINIC PRURIGO | 8 | 13 |
553 | 0 | 3 | 1129 1994 BRITISH MEDICAL JOURNAL 308(6944):1636-1636 READ AP THALIDOMIDE MAY BE A MUTAGEN - COMMENT | 11 | 13 |
554 | 2 | 4 | 1232 1996 AMERICAN JOURNAL OF OPHTHALMOLOGY 122(4):594-595 Ip M; Gorin MB Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide | 4 | 13 |
555 | 10 | 11 | 1306 1997 AMERICAN JOURNAL OF GASTROENTEROLOGY 92(1):169-170 Ball SC; Sepkowitz KA; Jacobs JL Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: Case report and review | 12 | 13 |
556 | 6 | 35 | 1318 1997 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 30(10):1199-1207 Moreira AL; Wang J; Sarno EN; Kaplan G Thalidomide protects mice against LPS-induced shock | 11 | 13 |
557 | 12 | 22 | 1339 1997 IMMUNOPHARMACOLOGY 35(3):203-212 Shannon EJ; Morales MJ; Sandoval F Immunomodulatory assays to study structure-activity relationships of thalidomide | 10 | 13 |
558 | 9 | 21 | 1342 1997 INFLAMMATION RESEARCH 46(10):392-397 Schneider J; Bruckmann W; Zwingenberger K Extravasation of leukocytes assessed by intravital microscopy: Effect of thalidomide | 5 | 13 |
559 | 0 | 0 | 1351 1997 JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 278(14):1135-1137 Marwick C Thalidomide back - Under strict control | 10 | 13 |
560 | 4 | 24 | 1398 1998 ANTICANCER RESEARCH 18(6A):4409-4413 Browne WL; Wilson WR; Baguley BC; Ching LM Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid | 5 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
561 | 2 | 4 | 1474 1998 PALLIATIVE MEDICINE 12(3):208-209 Deaner P Thalidomide for distressing night sweats in advanced malignant disease | 12 | 13 |
562 | 8 | 11 | 1475 1998 REVUE DE MEDECINE INTERNE 19(3):196-198 Lair G; Marie I; Cailleux N; Blot E; Boullie MC; Courville P; Lauret P; Levesque H; Courtois H Langerhans cell histiocytosis in adult patients: cutaneous and mucous localizations improving with thalidomide | 9 | 13 |
563 | 25 | 30 | 1481 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(12):1047-1052 Noormohamed FH; Youle MS; Higgs CJ; Kook KA; Hawkins DA; Lant AF; Thomas SD Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects | 13 | 13 |
564 | 10 | 31 | 1526 1999 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 118(2):315-321 Oliver SJ; Freeman SL; Corral LG; Ocampo CJ; Kaplan G Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis | 9 | 13 |
565 | 13 | 34 | 1537 1999 ELECTROPHORESIS 20(12):2425-2431 Meyring M; Chankvetadze B; Blaschke G Enantioseparation of thalidomide and its hydroxylated metabolites using capillary electrophoresis with various cyclodextrins and their combinations as chiral buffer additives | 2 | 13 |
566 | 16 | 32 | 1548 1999 IMMUNOLOGY LETTERS 68(2-3):325-332 Rowland TL; McHugh SM; Deighton J; Ewan PW; Dearman RJ; Kimber I Selective down-regulation of T cell-and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone | 10 | 13 |
567 | 19 | 39 | 1591 1999 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 13 |
568 | 0 | 0 | 1662 2000 BLOOD 96(11):323A-323A Estey E; Albitar M; Cortes J; Giles F; Thomas D; Koller C; Beran M; Kantarjian H Addition of thalidomide(T) to chemotherapy did not increase remission rate in poor prognosis AML/MDS. | 0 | 13 |
569 | 4 | 4 | 1685 2000 BRITISH JOURNAL OF HAEMATOLOGY 110(3):754-754 Gutheil J; Finucane D Thalidomide therapy in refractory solid tumour patients | 10 | 13 |
570 | 8 | 35 | 1788 2000 SEMINARS IN HEMATOLOGY 37(1):26-34 Thomas DA Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders | 9 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
571 | 65 | 116 | 1808 2001 ANNALS OF MEDICINE 33(8):516-525 Ginsburg PM; Dassopoulos T; Ehrenpreis ED Thalidomide treatment for refractory Crohn's disease: a review. of the history, pharmacological mechanisms and clinical literature | 9 | 13 |
572 | 32 | 67 | 1896 2001 CANCER 92(9):2364-2373 Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang XM; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck | 6 | 13 |
573 | 53 | 140 | 1919 2001 DRUG SAFETY 24(2):87-117 Clark TE; Edom N; Larson J; Lindsey LJ Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | 11 | 13 |
574 | 32 | 42 | 1978 2001 LUPUS 10(3):188-192 Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GRV Update on therapy - thalidomide in the treatment of lupus | 6 | 13 |
575 | 6 | 18 | 2008 2001 SEMINARS IN ONCOLOGY 28(6):588-592 Blade J; Esteve J; Rosinol L; Perales M; Montoto S; Tuset M; Montserrat E Thalidomide in refractory and relapsing multiple myeloma | 11 | 13 |
576 | 17 | 24 | 2164 2002 CLINICAL CANCER RESEARCH 8(11):3377-3382 Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma | 9 | 13 |
577 | 14 | 25 | 2228 2002 JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
578 | 22 | 28 | 2428 2003 CANCER RESEARCH 63(3):593-599 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins | 6 | 13 |
579 | 0 | 1 | 44 1961 JOURNAL OF PHARMACY AND PHARMACOLOGY 13:T117-& GREEN JN; BENSON BC SPECTROPHOTOMETRIC DETERMINATION OF THALIDOMIDE IN BODY FLUIDS | 11 | 12 |
580 | 5 | 14 | 171 1962 PEDIATRICS 30(4):654-& TAUSSIG HB THALIDOMIDE AND PHOCOMELIA | 2 | 12 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
581 | 4 | 17 | 258 1963 PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE 114(2):326-& FRANK O; HUTNER SH; SOBOTKA H; BAKER H TOXICITY TO PROTOZOA OF THALIDOMIDE BREAKDOWN PRODUCTS - COUNTERACTION BY NICOTINIC ACID AND GLUTAMINE | 8 | 12 |
582 | 0 | 0 | 259 1963 SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION 15(1):102-& NYSTROM C BIOCHEMICAL EFFECTS OF THALIDOMIDE - A PRELIMINARY REPORT | 8 | 12 |
583 | 1 | 10 | 305 1965 ACTA MEDICA SCANDINAVICA 177(6):783-& JENSEN MK CHROMOSOME ABERRATIONS IN HUMAN CELLS INDUCED BY THALIDOMIDE IN VITRO - PRELIMINARY REPORT | 4 | 12 |
584 | 2 | 6 | 352 1965 PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON 58(7):491-& SMITHELL.RW THALIDOMIDE LEGACY | 0 | 12 |
585 | 1 | 7 | 354 1965 PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON 58(7):497-& WOOLLAM DHM PRINCIPLES OF TERATOGENESIS - MODE OF ACTION OF THALIDOMIDE | 6 | 12 |
586 | 0 | 12 | 363 1966 BRITISH JOURNAL OF EXPERIMENTAL PATHOLOGY 47(2):186-& PEARN JH; VICKERS TH RABBIT THALIDOMIDE EMBRYOPATHY | 8 | 12 |
587 | 11 | 27 | 415 1967 AMERICAN JOURNAL OF VETERINARY RESEARCH 28(127):1823-& SZABO KT; STEELMAN RL EFFECTS OF MATERNAL THALIDOMIDE TREATMENT ON PREGNANCY FETAL DEVELOPMENT AND MORTALITY OF OFFSPRING IN RANDOM-BRED MICE | 12 | 12 |
588 | 6 | 27 | 420 1967 ARZNEIMITTEL-FORSCHUNG 17(11):1360-& GLEISS J GROWTH OF EMBRYOS OF SINAPIS ALBA INHIBITED BY N-PHTHALYGLUTAMIC ACID IMIDE(THALIDOMIDE) . NA-PHENYLETHYLBARBITURIC ACID (PHENOBARBITAL-NA) AND ALPHA-ETHYL-ALPHA-PHENYLGLUTARIMIDE)GLUTETHIMIDE) | 1 | 12 |
589 | 3 | 18 | 508 1970 MIKROCHIMICA ACTA (3):530-& PISCHEK G; KAISER E; KOCH H THIN-LAYER CHROMATOGRAPHY OF THALIDOMIDE AND ITS HYDROLYSIS PRODUCTS | 6 | 12 |
590 | 0 | 19 | 578 1973 PLASTIC AND RECONSTRUCTIVE SURGERY 51(1):93-95 ELSAHY NI MOBIUS SYNDROME ASSOCIATED WITH MOTHER TAKING THALIDOMIDE DURING GESTATION - CASE REPORT | 0 | 12 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
591 | 0 | 5 | 618 1976 ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 102(7):425-427 TAKEMORI S; TANAKA Y; SUZUKI JI THALIDOMIDE ANOMALIES OF EAR | 5 | 12 |
592 | 10 | 38 | 1029 1990 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 10(4):281-294 HUANG PHT; MCBRIDE WG THALIDOMIDE INDUCED ALTERATION IN SECONDARY STRUCTURE OF RAT EMBRYONIC DNA INVIVO | 6 | 12 |
593 | 4 | 6 | 1055 1992 BRITISH JOURNAL OF DERMATOLOGY 126(1):92-93 MOISSON YF; JANIER M; CIVATTE J THALIDOMIDE FOR RECURRENT ERYTHEMA MULTIFORME | 9 | 12 |
594 | 11 | 33 | 1082 1993 ACTA OPHTHALMOLOGICA 71(2):238-245 STROMLAND K; MILLER MT THALIDOMIDE EMBRYOPATHY - REVISITED 27 YEARS LATER | 4 | 12 |
595 | 4 | 17 | 1251 1996 CANCER LETTERS 101(1):21-24 Pollard M Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats | 8 | 12 |
596 | 11 | 43 | 1269 1996 INFLAMMATION 20(2):203-215 Kroger H; Miesel R; Dietrich A; Ohde M; Rajnavolgyi E; Ockenfels H Synergistic effects of thalidomide and poly(ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice | 1 | 12 |
597 | 6 | 22 | 1324 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 108(3):428-431 Hauschild A; Kroeger H; Mitchison NA; Ugrinovic S; Zwingenberger K Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift | 6 | 12 |
598 | 7 | 13 | 1388 1997 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):1-5 Huang PHT; McBride WG Interaction of [glutarimide-2-C-14]-thalidomide with rat embryonic DNA in vivo | 7 | 12 |
599 | 3 | 25 | 1440 1998 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 116(1):60-66 Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment | 9 | 12 |
600 | 13 | 66 | 1463 1998 MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
Page 2: 1 2 3 4 5 6 7 8 9
Generated by:
HistCite(Vlad).
Version: 2004.09.22